德国经股动脉主动脉瓣植入术的手术量与院内死亡率关系
基于德国强制性质量保证注册研究,分析2018和2019年接受择期或紧急经股动脉主动脉瓣植入术(TF-TAVI)的患者,评估医院手术量与风险调整后院内死亡率的关系。结果显示未调整死亡率与手术量负相关,但风险调整后关联弱且不一致,医院手术量对结局无临床相关性,建议直接评估风险调整死亡率而非手术量。
要点
- 风险调整后医院手术量与死亡率关联弱,2018年不显著,2019年虽显著但解释方差仅4.9%。
- 手术量截断值无法准确区分质量不可接受与可接受的医院。
- 应直接评估风险调整死亡率而非使用手术量作为质量指标。
核心结论
- 在德国2018和2019年择期TF-TAVI患者中,医院手术量与院内死亡率的关联弱且在不同分析方法下不一致,提示手术量对结局无临床相关性。
- 不建议使用手术量作为质量代理指标,应直接评估实际达到的风险调整死亡率。
研究设计与样本
- 使用德国AKL-KATH评分和EuroScore II进行风险调整,通过回归分析和手术量四分位数分析手术量与观察/预期死亡率比(O/E)的相关性。
主要发现
- 2018年平均观察院内死亡率为2.57±1.83%,2019年为2.36±1.60%。
- 未调整院内死亡率与医院手术量呈显著负相关(线性回归,两年均显著)。
- 风险调整后,2019年手术量与O/E显著相关(R2=0.049;P=0.046),2018年不显著(R2=0.027;P=0.14)。
- 2019年手术量解释O/E方差仅4.9%。
关键数值与推荐
- 任何手术量截断值均无法准确区分质量不可接受(O/E>95百分位)与可接受(O/E≤95百分位)或高于平均(O/E<1)的医院。
- 例如2019年截断值150仅排除两家质量不可接受医院中的一家,同时排除20家质量可接受或高于平均的医院(占所有医院25%)。
临床怎么用
- 临床质量评估应直接采用风险调整死亡率,而非医院手术量。
- 在限制医院准入且整体TAVI手术量高的医疗体系中,手术量作为质量指标价值有限。
局限性
- 数据来自限制医院准入且整体TAVI手术量高的医疗体系,结果可能不适用于其他医疗体系。
- 研究为观察性分析,可能存在未测量混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Studies assessing transfemoral transcatheter aortic valve implantation (TF-TAVI) showed lower rates of in-hospital mortality at high-volume hospitals and minimum caseloads were recommended to assure quality standards. METHODS AND RESULTS: All patients in the German mandatory quality assurance registry with elective or urgent TF-TAVI procedures in 2018 and 2019 at 81 and 82 hospitals, respectively, were analysed. Observed in-hospital mortality was adjusted to expected mortality by the German AKL-KATH score (O/E) as well as by the EuroScore II (O/E2). Hospital volume and O/E were correlated by regression analyses and volume quartiles. 18 763 patients (age: 81.1 ± 1.0 years, mean EuroSCORE II: 6.9 ± 1.8%) and 22 137 patients (mean age: 80.7 ± 3.5 years, mean EuroSCORE II: 6.5 ± 1.6%) were analysed in 2018 and 2019, respectively. The average observed in-hospital mortality was 2.57 ± 1.83% and 2.36 ± 1.60%, respectively. Unadjusted in-hospital mortality was significantly inversely related to hospital volume by linear regression in both years. After risk adjustment, the association between hospital volume and O/E was statistically significant in 2019 (R2 = 0.049; P = 0.046), but not in 2018 (R2 = 0.027; P = 0.14). The variance of O/E explained by the number of cases in 2019 was low (4.9%). Differences in O/E outcome between the first and the fourth quartile were not statistically significant in both years (1.10 ± 1.02 vs. 0.82 ± 0.46; P = 0.26 in 2018; 1.16 0 .97 vs. 0.74 ± 0.39; P = 0.084 in 2019). Any chosen volume cut-off could not precisely differentiate between hospitals with not acceptable quality (>95th percentile O/E of all hospitals) and those with acceptable (O/E ≤95th percentile) or above-average (O/E < 1) quality. For example, in 2019 a cut-off value of 150 would only exclude one of two hospitals with not acceptable quality, while 20 hospitals with acceptable or above-average quality (25% of all hospitals) would be excluded. CONCLUSION: The association between hospital volume and in-hospital mortality in patients undergoing elective TF-TAVI in Germany in 2018 and 2019 was weak and not consistent throughout various analytical approaches, indicating no clinical relevance of hospital volume for the outcome. However, these data were derived from a healthcare system with restricted access to hospitals to perform TAVI and overall high TAVI volumes. Instead of the unprecise surrogate hospital volume, the quality of hospitals performing TF-TAVI should be directly assessed by real achieved risk-adjusted mortality.
引用
- Bestehorn K, Bestehorn M, Zahn R, et al. Transfemoral aortic valve implantation: procedural hospital volume and mortality in Germany. Eur Heart J. 2023. PMID: 36459131. doi:10.1093/eurheartj/ehac698
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。